^
Association details:
| Biomarker: | EGFR exon 20 insertion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | BLU-451 (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions.
Published date:
05/25/2023
Excerpt:
As of the data cutoff, BLU-451 monotherapy was generally well tolerated, with early evidence of clinical activity in heavily pretreated pts with EGFR ex20ins–positive NSCLC.
DOI:
10.1200/JCO.2023.41.16_suppl.9064
Trial ID:
